Phase 2 Study of Axitinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the efficacy (clinical benefit rate) of single-agent axitinib in patients with recurrent or metastatic NPC, and its impact on disease progression.
Anthony TC Chan, MD, FRCP
Department of Clinical Oncology, The Chinese University of Hong Kong
Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee